Next Article in Journal
Ligands and Receptors Involved in the Sperm-Zona Pellucida Interactions in Mammals
Previous Article in Journal
Apoptosis in the Extraosseous Calcification Process
Previous Article in Special Issue
Transient Multivalent Nanobody Targeting to CD206-Expressing Cells via PH-Degradable Nanogels

Unraveling the In Vivo Protein Corona

Max Planck Institute for Polymer Research, Ackermannweg 10, 55128 Mainz, Germany
Dermatology Clinic, University Medical Center of the Johannes Gutenberg-University Mainz, Langenbeckstr 1, 55131 Mainz, Germany
Children’s Hospital, University Medical Center, Johannes Gutenberg University, 55128 Mainz, Germany
Author to whom correspondence should be addressed.
These authors contributed equally to this work.
Cells 2021, 10(1), 132;
Received: 7 December 2020 / Revised: 5 January 2021 / Accepted: 7 January 2021 / Published: 12 January 2021
(This article belongs to the Special Issue Nanoparticles in Cancer Immunotherapy)
Understanding the behavior of nanoparticles upon contact with a physiological environment is of urgent need in order to improve their properties for a successful therapeutic application. Most commonly, the interaction of nanoparticles with plasma proteins are studied under in vitro conditions. However, this has been shown to not reflect the complex situation after in vivo administration. Therefore, here we focused on the investigation of magnetic nanoparticles with blood proteins under in vivo conditions. Importantly, we observed a radically different proteome in vivo in comparison to the in vitro situation underlining the significance of in vivo protein corona studies. Next to this, we found that the in vivo corona profile does not significantly change over time. To mimic the in vivo situation, we established an approach, which we termed “ex vivo” as it uses whole blood freshly prepared from an animal. Overall, we present a comprehensive analysis focusing on the interaction between nanoparticles and blood proteins under in vivo conditions and how to mimic this situation with our ex vivo approach. This knowledge is needed to characterize the true biological identity of nanoparticles. View Full-Text
Keywords: protein corona; nanoparticle; in vivo; serum; plasma; biodistribution protein corona; nanoparticle; in vivo; serum; plasma; biodistribution
Show Figures

Figure 1

MDPI and ACS Style

Simon, J.; Kuhn, G.; Fichter, M.; Gehring, S.; Landfester, K.; Mailänder, V. Unraveling the In Vivo Protein Corona. Cells 2021, 10, 132.

AMA Style

Simon J, Kuhn G, Fichter M, Gehring S, Landfester K, Mailänder V. Unraveling the In Vivo Protein Corona. Cells. 2021; 10(1):132.

Chicago/Turabian Style

Simon, Johanna, Gabor Kuhn, Michael Fichter, Stephan Gehring, Katharina Landfester, and Volker Mailänder. 2021. "Unraveling the In Vivo Protein Corona" Cells 10, no. 1: 132.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop